Post-PCI anticoagulation with unfractionated heparin in acute coronary syndrome: insight from the STOPDAPT-3 trial

Back

ESC Professional Premium Access

Post-PCI anticoagulation with unfractionated heparin in acute coronary syndrome: insight from the STOPDAPT-3 trial

Session: Tailored approaches to cardiovascular therapy in acute coronary syndromes

Topic: Pharmacotherapy

Speaker: Doctor H. Watanabe (Hirakata, JP)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Hirotoshi Watanabe

Hirakata Kohsai Hospital, Hirakata (Japan)

2 presentations

1 follower

4 more presentations in this session

Effect of alirocumab on coronary plaque stratified by atherothrombotic risks

Speaker: Doctor Y. Ueki (Matsumoto, JP)

Lesion-level changes induced by low-density lipoprotein cholesterol lowering therapy in patients with acute myocardial infarction: the pre-specified PACMAN-AMI lesion-level analysis.

Speaker: Doctor F. Biccire (Bern, CH)

Real-world evidence supports superior efficacy of prasugrel over ticagrelor in individuals with acute coronary syndrome

Speaker: Doctor N. Kruger (Munich, DE)

A liberal blood transfusion strategy is safe in patients with myocardial infarction, anemia, and heart failure: lessons from MINT

Speaker: Doctor A. Goldsweig (Springfield, US)

Access the full session

Tailored approaches to cardiovascular therapy in acute coronary syndromes

Speakers: Doctor H. Watanabe, Doctor Y. Ueki, Doctor F. Biccire, Doctor N. Kruger, Doctor A. Goldsweig

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources